Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024

EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.

Balversa (erdafitinib), for the treatment of adult patients with unresectable or metastatic urothelial carcinoma, a cancer of the bladder and urinary system.

Eurneffy (epinephrine), the first emergency treatment against allergic reactions that is administered as a nasal spray, not as an injection.

mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine)

Ordspono* (odronextamab), for the treatment of follicular lymphoma and diffuse large B-cell lymphoma

Piasky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria

Tauvid (flortaucipir (18F)), for positron emission tomography (PET) imaging of the brain in adult patients with cognitive impairmen

Winrevair* (sotatercept), to treat adult patients with pulmonary arterial hypertension

Steqeyma (ustekinumab), a biosimilar medicine and two generic medicines: Enzalutamide Viatris (enzalutamide) for the treatment of prostate cancer. Nilotinib Accord (nilotinib) for the treatment of Philadelphia chromosome positive chronic myelogenous leukaemia.

Leave a Comment

Your email address will not be published. Required fields are marked *